



**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Taryn-Gene S. Durkin
Michelle A. Cimbalia
Michael E. Ray
Robert E. Solich
Eric K. Sertle
Michael Q. Lee
Steven R. Ludwig
John M. Cowitt
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugalsky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffery T. Helweg
Heidi L. Kous
Crystal D. Sayles
Edward W. Yee
Albert L. Fenn
Donald R. Benowitz
Peter A. Jackson
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent I. Capasso
Albert J. Fasulo II
Elzora Elison Floyd
W. Russell Swindell

Thomas C. Fiea
Brian J. Del Buono
Virgil Lee Beaton
Reginald D. Lucas
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Under
Rae Lynn Pringman
Jane Shershenovich
Lawrence J. Carroll

Senior Counsel
Samuel I. Fox
Kenneth C. Bass III

Registered Patent Agents
Karen R. Markwicz
Andrea J. Kinsage
Nancy J. Lech
Joseph M. Conrad
Amy E. Summerfield
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Scheritz
Angelique G. Uy
Boris A. Mavrenko
Mary B. Tung

*Admitted only in New York
*Admitted only in California
*Admitted only in Texas

TECH CENTER
MAR 14 2002
11:30 AM
2800

MAR 14 2002

RECEIVED

March 12, 2002

INTERNET ADDRESS:
JGOLD@SKGF.COM

Art Unit 1633

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Utility Patent Application
App'l. No. 09/964,678; Filed: September 28, 2001
For: **Transgenic Animals and Cell Lines for Screening Drugs
Effective for the Treatment or Prevention of Alzheimer's
Disease**

Inventors: de la Monte *et al.*
Our Ref: 0609.4370002/RWE/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Listing of the cited documents on Form PTO-1449 (9 sheets);
3. A copy of each of the forty (40) cited documents on Form PTO-1449; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents


March 12, 2002

Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

RWE:FRC:dew
Enclosures

P:\USERS\DWRIGHT\General\ROB ESMOND\IDS-SKGF-CV-LTR-0609 4370002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

MAR 14 2002

#9
RECEIVED

In re application of:

de la Monte *et al.*

Appl. No. 09/964,678

Filed: September 28, 2001

For: **Transgenic Animals and Cell
Lines for Screening Drugs
Effective for the Treatment or
Prevention of Alzheimer's Disease**

Confirmation No. 3649

Art Unit: 1633

Examiner: *To be assigned*

Atty. Docket: 0609.4370002/RWE/FRC

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is provided.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following, in regards to non-English language document AL1 cited on Form PTO 1449:

Document AL1, European Patent No. EP 0 263 740, is in the French language. An English language abstract of document AL1 is attached as document AT7.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications which are directed to related technical subject matter: U.S. Patent Application No. 09/380,203, filed April 25, 2000; U.S. Patent Application No. 09/964,666, filed September 28, 2001; U.S. Patent Application No. 09/964,412, filed September 28, 2001; and

U.S. Patent Application No. 09/964,667, filed September 28, 2001. The specifications of these applications are identical to one another, and are therefore "substantially cumulative." Accordingly, pursuant to 37 CFR § 1.98(c), a single copy of this specification is submitted herewith as document AS8. The claims currently pending from US patent application Nos. 09/380,203, 09/964,666, 09/964,412, and 09/964,667 are additionally submitted herewith as documents AT8, AR9, AS9 and AT9, respectively.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Date: March 12, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600